A/Prof. Andrew Weickhardt
MEDICAL ONCOLOGIST | SENIOR CLINICAL RESEARCH FELLOW
A/Prof. Andrew Weickhardt
<p><em>I love using cutting edge science to improve the outcomes for cancer patients who I see each day in the clinic. Every day is different as technology and treatment constantly evolves. I work i<em>n partnership with<em> a team of</em> laboratory scientists</em> focused on harnessing these changes.</em></p>
<p>My main areas of clinical responsibility are the management of patients with genitourinary cancer and involvement in clinical trials in this patient population. I also work in drug development and early phases of drug development.</p>
<p>My translational cancer research interests involve the optimisation of immunotherapy and precision medicine. This involves the identification of novel targets, refinement of biomarker assays, monitoring and evaluation of therapeutic response to therapy, and identification of resistance mechanisms to therapy. I design clinical trials that aim to improve upon standard therapies through new drugs. I analyse patient clinical outcomes and match the results of the trial to profiles of patients' immune cells and cancer cells in order to identify how to predict which patients may benefit the most from these types of treatment in the future. </p>
<p>My aim is to try and find the right combination of immune therapy or targeted therapy for the right patient so that durable control of cancer may be achieved with minimal side effects. My work has appeared in publications such as the New England Journal of Medicine, Journal of Clinical Oncology, Cancer, Clinical Cancer Research and the British Journal of Cancer.</p>
<h3>
</h3>
<h3>Education</h3>
<p>MBBS (Hons), University of Melbourne, Australia
</p>
<p>Fellowship of the Royal Australasian College of Physicians (medical oncology)
</p>
<p>
DMed Sc, University of Melbourne: Thesis title: Molecular determinates of therapeutic response to targeted therapies in metastatic colorectal cancer</p>
<h3>Appointments</h3>
<p>Associate Professor, School of Cancer Medicine, La Trobe University</p>
<p>
Translational Scientist, Olivia Newton-John Cancer Research Institute
</p>
<p>Medical Oncologist, Olivia Newton-John Cancer and Wellness Centre
</p>
<h3>Achievements</h3>
<p>
2015 Pfizer Australia Cancer Research Grant </p>
<p>2015 Austin Medical Research Foundation Grant</p>
<p>2011-2012 Post doctoral Scholarship University of Colorado Cancer Centre </p>
<p>2010, 2011 ASCO Cancer Foundation Merit Award </p>
<p>
2009-2010 National Health and Medical Research Council post graduate Fellowship </p>
<p>2009 Roche Medical Oncology Award (HOTT Fellowship)</p>
<p>2009 Henry Pollack FRACP research entry scholarship </p>
<p>2002 1st placed student final year and over all 6 years at University of Melbourne Medical School </p>
<p>
</p>
<h3>Recent Publications</h3>
<p>Louise Emmett, Ur Metser, Glenn Bauman, Rodney J Hicks, Andrew Weickhardt, Ian D Davis, Shonit Punwani, Gregory R Pond, Sue Siew-Chen Chua, Bao Ho, Edward Johnston, Frederic Pouliot, Andrew Scott ; A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance and Patient Outcomes, Journal of Nuclear Medicine, November 2018</p>
<p>A Hamid, F Ha, O Das, A Weickhardt Communicating prognosis of patients with advanced cancer between health care providers: a tertiary cancer center review of written correspondence, Annals of Palliative Medicine, 2018</p>
<p>Anis Hamid, K Wilson, A Vincent…, A Weickhardt; Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration resistant prostate cancer, Asia‐Pacific Journal of Clinical Oncology, 2018</p>
<p>A. Weickhardt, T Price, G Chong, V Gebski, N Pavlakis, T Johns, A Azad, E Skrinos, K Fluck, A Dobrovic, R Salemi, A Scott, J Mariadason, N Tebbutt: Dual targeting of the epidermal growth factor receptor (EGFR) using the combination of cetuximab and erlotinib: pre-clinical evaluation and results of the phase II DUX study in chemotherapy refractory, advanced colorectal cancer, Journal of Clinical Oncology 2012, May 1. Describes a novel combination of targeted therapy and potential biomarkers</p>
<p>R Doebele, A Pilling, D Aisner, T. Kutateladze, A Le, A. Weickhardt, K Kondo, D Linderman, L. Heasley, W. Franklin, M Varella-Garcia, R Camidge: Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer, Clinical Cancer Research, 2012 Mar 1;18(5):1472-82 Outlines novel resistance mechanisms to targeted therapy</p>
<p> </p>
<p>Ph: +61 3 9496 9923</p>
<p>
E: andrew.weickhardt@onjcri.org.au</p>